The joint health space is in good shape in most markets globally with (mostly supplement) sales sitting at about $2bn. Strong links have been established between certain marquee nutrients like glucosamine and chondroitin and joint health/osteoarthritis benefits in the minds of millions of consumers.
However, virtually no approved health claims for the ability of these kinds of dietary supplements to benefit joint health, with regulators questioning the use of diseased populations, amongst other things.
Speaking to Stephen Daniells, Dr Udani explains which measures can be used to establish joint health benefits in a healthy population, and why measures of inflammation may not be suitable.
Dr Udani, also CEO of Medicus Research, a CRO, also highlights how a clinical trial can be designed to support the joint health potential of an ingredient or product.